Topline results were announced from two phase 3 trials evaluating itepekimab in former smokers with inadequately controlled COPD.

Regeneron and Sanofi face setbacks as itepekimab stumbles in phase 3. Click here to read why I believe SNY and REGN stocks ...

Paris: Sanofi has announced that the AERIFY-1 phase 3 study evaluating itepekimab in former smokers with inadequately ...

Regeneron (NASDAQ:REGN) shares fell ~18% to reach a new 52-week low as a Phase 3 trial failure for its antibody therapy ...

Topline results were announced from two phase 3 trials evaluating itepekimab, an anti-interleukin-33 monoclonal antibody, in former smokers with inadequately controlled chronic obstructive ...

Sanofi & Regeneron announce itepekimab meet the primary endpoint in one of two COPD phase 3 studies: Paris Saturday, May 31, 2025, 10:00 Hrs [IST] The AERIFY-1 phase 3 study evalu ...

Shares in both companies were lower after one study met the primary goal and a second missed its main target in their drug ...

Sanofi and Regeneron said that drug candidate Itepekimab met the primary goal in one of two chronic obstructive pulmonary disease phase 3 studies, but didn't hit the main objective of a second trial.

Sanofi’s plans to submit itepekimab to regulators for approval this year have been thrown into doubt after the ...

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

In the trials, patients were randomized to receive itepekimab every two weeks (AERIFY-1: n=375; AERIFY-2: n=326), every four weeks (AERIFY-1: n=377; AERIFY-2: n=303), or placebo (AERIFY-1 ...